Quality by Design—


An Indispensable Approach to Accelerate Biopharmaceutical Product Development

M. Amin Khan Cristiana Campa Editors





www.pda.org/bookstore



Quality by Design— An Indispensable Approach to Accelerate Biopharmaceutical Product Development

M. Amin Khan Cristiana Campa Editors

To order the book, please visit: go.pda.org/QbD



Parenteral Drug Association, Inc. – *Connecting People, Science and Regulation,* Bethesda, MD 20815

© 2021 Parenteral Drug Association, Inc.

All rights reserved. 2021

23 22 21 20 19 18 17 16 1 2 3 4 5

ISBN: 978-1-945584-22-0



TABLE OF CONTENTS

ı	Pre	face	V	
I	Foreward			
PART I: INTRODUCTION				1
ı	Intr	roduction	2	
		Quality by Design Principles	3	
		A Case Study	8	
PART II : PRODUCT UNDERSTANDING			15	
:	Sec	tion 1: Critical Quality Attributes and Ranges	16	
	1.	Critical Quality Attribute Determination and Establishing Acceptable	10	
	_	Ranges for Monoclonal Antibodies	18	
2	2.	Critical Quality Attribute Assessment and Definition of Acceptable Limits for IgG1 Monoclonal Antibodies	33	
į	3.	Critical Quality Attributes Acceptance Criteria and Patient-Centric Quality Standards	50	
4	4.	Biopharmaceutical Analytical Acceleration Strategies: Platforms, Critical Quality Attributes, and Specifications	60	
	5.	Critical Quality Attributes and Ranges for a Glycoconjugate-Based Vaccine in Development: A Case Study	72	
9	Sec	tion 2: Formulation Development	91	
	6.	Identification of Critical Quality Attributes in Adjuvanted Vaccines:		
		An Essential Step for Enabling Acceleration and Cost-Effective Formulation Development	93	
	7.	Formulation and Product Development of a mAb1: A Case Study in	,,	
		Acceleration at Various Stages of Product Development	112	
	Sec	tion 3: Stability Modeling	131	
	8.	Using Prior Knowledge for Stability Modeling of Biological		
		Therapeutic Agents to Assign Shelf Life	133	
9	9.	Stability Modeling in Quality by Design: Accelerating Formulation		
		Development and Predicting Shelf Life of Vaccine Products	169	
	10.	Stability Modeling for Biopharmaceutical Process Intermediates	200	

Quality by Design—

An Indispensable Approach to Accelerate Biopharmaceutical Product Development

Section 4: Comparability	226	
11. Comparability Assessment for Vaccines Development and Lifecycle	228	
PART III: PROCESS UNDERSTANDING AND MODELING	238	
Section 5: Process Understanding and Modeling 12. Using Quality-by-Design Principles to Increase Process Understanding for a mAb Drug Substance Manufacturing Process	239 241	
Approach to Speeding Up Process Understanding Without Compromising on Quality: A Vaccine Case Study	268	
 Accelerating Product and Process Development Through a Model-Centric Approach 	285	
PART IV: ANALYTICAL STRATEGY AND MODELING	339	
Section 6: Analytical Strategy and Modeling 15. Leveraging Quality-by-Design Principles to Accelerate Analytical Strategy: A Case Study for Glycoconjugate-Based Vaccines	340	
Case Study for divided in divided in the Study for divided in the	363	
17. Accelerating Attribute-Focused Analytical Development	396	
18. Predictive Modeling in the Analytical Space	412	
PART V: PLATFORM KNOWLEDGE		
Section 7: Platform Knowledge 19. Platform Knowledge to Accelerate Adenovirus-Based Vaccine Development	421 423	
 mRNA Vaccines: A Disruptive Platform Technology To Accelerate Development 	460	
 Platform Raw Material Risk Assessment for a Monoclonal Antibody Drug Substance Process 	482	
PART VI: CONCLUSIONS		
Conclusions		
Index	501	